312 related articles for article (PubMed ID: 25609062)
1. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
Lombardi AJ; Hoskins EE; Foglesong GD; Wikenheiser-Brokamp KA; Wiesmüller L; Hanenberg H; Andreassen PR; Jacobs AJ; Olson SB; Keeble WW; Hays LE; Wells SI
Clin Cancer Res; 2015 Apr; 21(8):1962-72. PubMed ID: 25609062
[TBL] [Abstract][Full Text] [Related]
2. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.
Pfäffle HN; Wang M; Gheorghiu L; Ferraiolo N; Greninger P; Borgmann K; Settleman J; Benes CH; Sequist LV; Zou L; Willers H
Cancer Res; 2013 Oct; 73(20):6254-63. PubMed ID: 23966292
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents.
Kee Y; Huang M; Chang S; Moreau LA; Park E; Smith PG; D'Andrea AD
Mol Cancer Res; 2012 Mar; 10(3):369-77. PubMed ID: 22219386
[TBL] [Abstract][Full Text] [Related]
4. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
Kachnic LA; Li L; Fournier L; Willers H
Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
[TBL] [Abstract][Full Text] [Related]
5. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
Weaver AN; Cooper TS; Rodriguez M; Trummell HQ; Bonner JA; Rosenthal EL; Yang ES
Oncotarget; 2015 Sep; 6(29):26995-7007. PubMed ID: 26336991
[TBL] [Abstract][Full Text] [Related]
6. Defects in the Fanconi Anemia Pathway and Chromatid Cohesion in Head and Neck Cancer.
Stoepker C; Ameziane N; van der Lelij P; Kooi IE; Oostra AB; Rooimans MA; van Mil SE; Brink A; Dietrich R; Balk JA; Ylstra B; Joenje H; Feller SM; Brakenhoff RH
Cancer Res; 2015 Sep; 75(17):3543-53. PubMed ID: 26122845
[TBL] [Abstract][Full Text] [Related]
7. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients.
van Zeeburg HJ; Snijders PJ; Pals G; Hermsen MA; Rooimans MA; Bagby G; Soulier J; Gluckman E; Wennerberg J; Leemans CR; Joenje H; Brakenhoff RH
Cancer Res; 2005 Feb; 65(4):1271-6. PubMed ID: 15735012
[TBL] [Abstract][Full Text] [Related]
8. Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
Chandrasekharappa SC; Chinn SB; Donovan FX; Chowdhury NI; Kamat A; Adeyemo AA; Thomas JW; Vemulapalli M; Hussey CS; Reid HH; Mullikin JC; Wei Q; Sturgis EM
Cancer; 2017 Oct; 123(20):3943-3954. PubMed ID: 28678401
[TBL] [Abstract][Full Text] [Related]
9. Preventing over-resection by DNA2 helicase/nuclease suppresses repair defects in Fanconi anemia cells.
Karanja KK; Lee EH; Hendrickson EA; Campbell JL
Cell Cycle; 2014; 13(10):1540-50. PubMed ID: 24626199
[TBL] [Abstract][Full Text] [Related]
10. Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
Du W; Amarachintha S; Wilson AF; Pang Q
Sci Rep; 2016 Feb; 6():22167. PubMed ID: 26916217
[TBL] [Abstract][Full Text] [Related]
11. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
Villamar Cruz O; Prudnikova TY; Araiza-Olivera D; Perez-Plasencia C; Johnson N; Bernhardy AJ; Slifker M; Renner C; Chernoff J; Arias-Romero LE
Oncotarget; 2016 Nov; 7(47):76590-76603. PubMed ID: 27740936
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.
Montanuy H; Martínez-Barriocanal Á; Antonio Casado J; Rovirosa L; Ramírez MJ; Nieto R; Carrascoso-Rubio C; Riera P; González A; Lerma E; Lasa A; Carreras-Puigvert J; Helleday T; Bueren JA; Arango D; Minguillón J; Surrallés J
Clin Cancer Res; 2020 Jun; 26(12):3044-3057. PubMed ID: 32005748
[TBL] [Abstract][Full Text] [Related]
13. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.
Kennedy RD; Chen CC; Stuckert P; Archila EM; De la Vega MA; Moreau LA; Shimamura A; D'Andrea AD
J Clin Invest; 2007 May; 117(5):1440-9. PubMed ID: 17431503
[TBL] [Abstract][Full Text] [Related]
14. The non-homologous end-joining activity is required for Fanconi anemia fetal HSC maintenance.
Nie Y; Li Y; Li X; Wilson AF; Pang Q
Stem Cell Res Ther; 2019 Mar; 10(1):114. PubMed ID: 30925933
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of non-homologous end joining in Fanconi Anemia cells results in rescue of survival after interstrand crosslinks but sensitization to replication associated double-strand breaks.
Eccles LJ; Bell AC; Powell SN
DNA Repair (Amst); 2018 Apr; 64():1-9. PubMed ID: 29459202
[TBL] [Abstract][Full Text] [Related]
16. Generating New FANCA-Deficient HNSCC Cell Lines by Genomic Editing Recapitulates the Cellular Phenotypes of Fanconi Anemia.
Errazquin R; Sieiro E; Moreno P; Ramirez MJ; Lorz C; Peral J; Ortiz J; Casado JA; Roman-Rodriguez FJ; Hanenberg H; Río P; Surralles J; Segrelles C; Garcia-Escudero R
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918752
[TBL] [Abstract][Full Text] [Related]
17. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
[TBL] [Abstract][Full Text] [Related]
18. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.
Dickreuter E; Eke I; Krause M; Borgmann K; van Vugt MA; Cordes N
Oncogene; 2016 Mar; 35(11):1353-62. PubMed ID: 26073085
[TBL] [Abstract][Full Text] [Related]
19. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.
Hernandez AL; Young CD; Bian L; Weigel K; Nolan K; Frederick B; Han G; He G; Devon Trahan G; Rudolph MC; Jones KL; Oweida AJ; Karam SD; Raben D; Wang XJ
Clin Cancer Res; 2020 Jun; 26(12):3058-3070. PubMed ID: 32139402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
